신경성 폭식증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Bulimia Nervosa Insights and Trends

• Bulimia Nervosa is a serious psychiatric eating disorder characterized by recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting, excessive exercise, fasting, or misuse of laxatives to prevent weight gain. The disorder is strongly associated with distorted body image, excessive concern about body weight, and emotional distress.
• Diagnosis relies on comprehensive clinical and psychiatric evaluation supported by standardized diagnostic criteria such as DSM-5 guidelines. Assessment includes evaluation of eating behaviors, compensatory patterns, psychological symptoms, and physical health status. Laboratory testing and physical examination are often performed to identify nutritional deficiencies, metabolic abnormalities, and complications associated with recurrent purging behaviors.
• The current treatment landscape is primarily multidisciplinary, combining psychotherapy, nutritional rehabilitation, behavioral interventions, and pharmacological management to achieve symptom control and relapse prevention.
• Pharmacological therapy remains limited, with PROZAC (fluoxetine) being the only FDA-approved medication for bulimia nervosa at a dose of 60 mg/day. It provides moderate efficacy in reducing binge-purge frequency and relapse risk but is largely symptomatic rather than disease-modifying.
• Off-label pharmacological options such as sertraline, escitalopram, venlafaxine, topiramate, and atypical antipsychotics are used in select patients, mainly targeting comorbid psychiatric symptoms rather than core disease pathology.
• A key structural limitation of the market is the absence of any emerging drug pipeline in bulimia nervosa; there are currently no active emerging pharmacological therapies in development specifically for this indication at a meaningful stage of research or commercialization.
• Despite increasing awareness, Bulimia Nervosa continues to represent a substantial clinical and socioeconomic burden due to underdiagnosis, high relapse rates, psychiatric comorbidities, and long-term treatment requirements. Growing mental health awareness, improved access to specialized care, and expanding recognition of eating disorders are contributing to a rising diagnosed patient population globally.

DelveInsight's 'Bulimia Nervosa - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the bulimia nervosa, historical and forecasted epidemiology, as well as the bulimia nervosa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Bulimia Nervosa market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates bulimia nervosa patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Bulimia Nervosa and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Bulimia Nervosa Understanding and Treatment Algorithm

Bulimia Nervosa Overview and Diagnosis

Bulimia Nervosa is a serious eating disorder characterized by recurrent binge-eating episodes followed by compensatory behaviors such as self-induced vomiting, fasting, excessive exercise, or misuse of laxatives to prevent weight gain. The condition is strongly associated with body image dissatisfaction, anxiety, depression, and low self-esteem, and commonly affects adolescents and young adults. If untreated, it can lead to severe physical and psychological complications. Diagnosis of Bulimia Nervosa is primarily based on clinical and psychiatric evaluation using DSM-5 criteria. Physicians assess eating behaviors, compensatory patterns, psychological symptoms, and body image concerns through patient interviews and screening tools. Laboratory tests and physical examinations may also be conducted to identify nutritional deficiencies and medical complications.

Bulimia Nervosa Treatment

Treatment of bulimia nervosa typically involves a combination of psychotherapy, nutritional rehabilitation, and pharmacotherapy aimed at reducing binge-eating and compensatory purging behaviors while addressing underlying psychological distress. Cognitive behavioral therapy (CBT), particularly CBT-BN, is considered the first-line treatment and focuses on correcting maladaptive eating patterns, distorted body image, and unhealthy coping mechanisms. Nutritional counseling and structured meal planning are used to restore regular eating behaviors and reduce binge triggers. Pharmacologically, PROZAC (fluoxetine) remains the only FDA-approved medication for bulimia nervosa and is commonly prescribed at 60 mg/day to reduce binge-purge frequency and relapse risk. Other antidepressants and psychiatric medications may be used off-label in patients with comorbid anxiety, depression, or inadequate response to fluoxetine. Severe or medically unstable cases may require hospitalization for electrolyte correction, cardiac monitoring, and intensive psychiatric care. Long-term management often includes ongoing psychotherapy, family support, and relapse-prevention strategies to maintain recovery and improve quality of life.

Bulimia Nervosa Unmet Needs

The section "Unmet Needs of Bulimia Nervosa" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Diagnostic and Disease Recognition Gaps

2. High Relapse and Chronicity Burden

3. Psychotherapy Access and Effectiveness Challenges

4. Psychiatric and Medical Comorbidity Burden, and others.....

Comprehensive unmet needs insights in Bulimia Nervosa and their strategic implications are provided in the full report.

Bulimia Nervosa Epidemiology

Key Findings from Bulimia Nervosa Epidemiological Analysis and Forecast

• The lifetime prevalence rates for bulimia nervosa ranged from 0.3-4.6% in females and from 0.1-1.3% in males.
• The pooled overall lifetime prevalence rate rose to 1.4% when using only studies that applied DSM-5 criteria (18%; all in Western countries).
• According to a secondary analysis, during the period from 1990 to 2021, the number of individuals affected by bulimia nervosa increased by 67%, rising from 7,416,420 cases to 12,367,024 cases.
• One-year prevalence of bulimia nervosa is 0.32% for females and 0.05% for males.

Bulimia Nervosa Drug Analysis & Competitive Landscape

Approved Therapies for Acromegaly

Bulimia Nervosa Pipeline Analysis

Bulimia Nervosa Key Players, Market Leaders, and Emerging Companies

Bulimia Nervosa Drug Updates

Bulimia Nervosa Market Outlook

The bulimia nervosa treatment market is expected to witness gradual but meaningful growth driven by increasing awareness of eating disorders, rising diagnosis rates, expanding mental health infrastructure, and growing demand for integrated psychiatric care. Treatment of bulimia nervosa currently relies on a multidisciplinary approach involving psychotherapy, nutritional rehabilitation, behavioral interventions, and pharmacological management. Cognitive behavioral therapy (CBT) remains the clinical gold standard and is widely recommended as the first-line intervention due to its proven effectiveness in reducing binge-eating and compensatory purging behaviors. Additional non-pharmacological approaches, such as interpersonal therapy, dialectical behavioral therapy, family-based therapy, nutritional counseling, and digital mental health programs, are also increasingly incorporated into long-term disease management strategies. However, despite the broad use of psychotherapy, pharmacological treatment remains a critical component of care, particularly in patients with moderate-to-severe disease, psychiatric comorbidities, recurrent relapse, or inadequate response to behavioral therapy alone.

Within the pharmacological landscape, PROZAC (fluoxetine) continues to dominate the market as the only FDA-approved medication specifically indicated for bulimia nervosa. Its long-established efficacy in reducing binge-purge frequency, improving impulse control, and lowering relapse risk has sustained its position as the standard pharmacological therapy for nearly three decades. The widespread availability of generic fluoxetine has further strengthened treatment accessibility and prescription penetration globally, although genericization has simultaneously reduced commercial exclusivity and market value growth. Beyond fluoxetine, several psychiatric medications are used off-label in clinical practice, including SSRIs such as sertraline and escitalopram, SNRIs such as venlafaxine, anticonvulsants like topiramate, and atypical antipsychotics in select patient populations. These therapies are primarily utilized to manage associated depression, anxiety, obsessive-compulsive symptoms, impulsivity, or treatment-resistant binge-purge behaviors, although their evidence base remains comparatively limited and inconsistent.

The absence of emerging pharmacological innovation further highlights the dependency of the market on legacy SSRI-based treatment approaches that primarily provide symptomatic management rather than disease modification. Current therapies fail to adequately address long-term relapse prevention, impulse regulation, reward-circuit dysfunction, and coexisting psychiatric burden in many patients. As a result, significant unmet needs persist across treatment-resistant disease, chronic recurrent patients, adolescent populations, and patients with severe psychiatric comorbidities. Although growing research into gut-brain signaling, serotonergic dysfunction, and behavioral neurocircuitry may eventually create opportunities for future targeted therapies, the current market remains commercially stagnant with minimal pipeline diversification.

Industry Experts and Physician Views for Bulimia Nervosa

To keep up with Bulimia Nervosa market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on Bulimia Nervosa, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in bulimia nervosa, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of North Carolina at Chapel Hill, the Berlin Institute of Health at Charite, and the University of Nottingham, etc. were contacted. Their opinion helps understand and validate current and emerging bulimia nervosa therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in bulimia nervosa.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of bulimia nervosa, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of bulimia nervosa, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of the current treatments will have an impact on the current treatment landscape.
• A detailed review of the bulimia nervosa market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM bulimia nervosa market.

Report Insights

• Bulimia Nervosa Patient Population Forecast
• Bulimia Nervosa Therapeutics Market Size
• Bulimia Nervosa Pipeline Analysis
• Bulimia Nervosa Market Size and Trends
• Bulimia Nervosa Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Bulimia Nervosa Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Bulimia Nervosa Treatment Addressable Market (TAM)

Report Assessment

• Bulimia Nervosa Current Treatment Practices
• Bulimia Nervosa Unmet Needs
• Bulimia Nervosa Clinical Development Analysis
• Bulimia Nervosa Market Attractiveness
• Bulimia Nervosa Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the bulimia nervosa market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What can be the future treatment paradigm of bulimia nervosa?
• What are the disease risks, burdens, and unmet needs of bulimia nervosa? What will be the growth opportunities across the 7MM concerning the patient population with bulimia nervosa?
• What are the current options for the treatment of bulimia nervosa? What are the current guidelines for treating bulimia nervosa in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the bulimia nervosa market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. News Flow

5. Epidemiology and Market Forecast Methodology

6. Bulimia Nervosa Market Overview at a Glance

• 6.2. Market Share of Bulimia Nervosa by Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Bulimia Nervosa by Therapies (%) in the 7MM in 2036

7. Disease Background and Overview of Bulimia Nervosa

• 7.1. Introduction
• 7.2. Causes of Bulimia Nervosa
• 7.3. Risk Factors
• 7.4. Signs and Symptoms
• 7.5. Diagnosis
• 7.6. Stages

8. Treatment

• 8.1. Treatment Algorithm

9. Epidemiology and Patient Population of Bulimia Nervosa

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of Bulimia Nervosa in the 7MM
• 9.4. United States
  • 9.4.1. Total Diagnosed Prevalent Cases of Bulimia Nervosa in the United States
  • 9.4.2. Gender-specific Diagnosed Prevalent Cases of Bulimia Nervosa in the United States
  • 9.4.3. Age-Specific Diagnosed Prevalent Cases of Bulimia Nervosa in the United States
  • 9.4.4. Total Treated Cases of Bulimia Nervosa in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Bulimia Nervosa in EU4 and the UK
  • 9.5.2. Gender-specific Diagnosed Prevalent Cases of Bulimia Nervosa in EU4 and the UK
  • 9.5.3. Age-specific Diagnosed Prevalent Cases of Bulimia Nervosa in EU4 and the UK
  • 9.5.4. Total Treated Cases of Bulimia Nervosa in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Bulimia Nervosa in Japan
  • 9.6.2. Gender-specific Diagnosed Prevalent Cases of Bulimia Nervosa in Japan
  • 9.6.3. Age-specific Diagnosed Prevalent Cases of Bulimia Nervosa in Japan
  • 9.6.4. Total Treated Cases of Bulimia Nervosa in Japan

10. Patient Journey

11. Bulimia Nervosa: 7MM Analysis

• 11.1. Key Findings
• 11.2. Market Outlook
• 11.3. Conjoint Analysis
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions
• 11.5. Total Market Size of Bulimia Nervosa in the 7MM
• 11.6. The United States
  • 11.6.1. Total Market Size of Bulimia Nervosa in the United States
  • 11.6.2. Market Size of Bulimia Nervosa by Therapies in the United States
• 11.7. EU4 and the UK
  • 11.7.1. Total Market Size of Bulimia Nervosa in the EU4 and the UK
  • 11.7.2. Market Size of Bulimia Nervosa by Therapies in EU4 and the UK
• 11.8. Japan
  • 11.8.1. Total Market Size of Bulimia Nervosa in Japan
  • 11.8.2. Market Size of Bulimia Nervosa by Therapies in Japan

12. Unmet Needs of Bulimia Nervosa

13. SWOT Analysis of Bulimia Nervosa

14. KOL Views of Bulimia Nervosa

• 14.1. Expert/KOL Interview Highlights

15. Market Access and Reimbursement

• 15.1. The US
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. Japan
• 15.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 15.5. Market Access and Reimbursement of Bulimia Nervosa

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight